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Ovariancanceristhemostcommoncauseofmortalityoftumorsfromgynecologicoriginandisoftendiagnosedafterpatientshave
already progressed to advanced disease stage. The current standard of care for treatment of ovarian cancer includes cytoreductive
surgeryfollowedbyadjuvantchemotherapy.Unfortunately,manypatientswillrecurandultimatelydiefromtheirdisease.Targeted
therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Angiogenesis inhibitors have shown
success in many tumor types and have also demonstrated promise in trials involving patients with ovarian cancer. PARP inhibitors
may be potentially active agents in patients with BRCA-associated ovarian cancer. Trials that have evaluated combinations of
targeted agents have often revealed untoward toxicities, thus tempering enthusiasm for this approach.
1.Introduction
Ovarian cancer is the most common cause of mortality
from gynecologic cancer and will be responsible for 14600
cancerrelateddeathsthisyear.Secondarytovaguepresenting
symptoms and the lack of eﬀective screening, most patients
will present with advanced disease. The current standard
of care for ovarian cancer therapy is surgery followed
by adjuvant carboplatin and taxane-based chemotherapy.
Unfortunately, these protocols often do not allow for cure
at initial diagnosis, and many patients will often recur
and eventually die from their disease. Chemoresistance is
an important hurdle in the treatment of recurrent cancer.
Targeted therapy has subsequently come to the forefront of
research and clinical trials in an eﬀort to overcome resistant
disease and achieve improvement in patient outcomes.
2. Epidemiology
Ovarian cancer is the second most common gynecologic
malignancy,butisthemostcommoncauseofmortalityfrom
gynecologic cancer. It accounts for about 3 percent of all
cancers among women and is the ﬁfth most common cause
of cancer-related death in women [1]. Approximately 21550
cases will be diagnosed and 14600 deaths will occur this year
[2].
Surveillance Epidemiology and End Results (SEER)
database shows that the incidence of ovarian cancer has
decreased over the past 30 years [2]. Age-based incidence
increases from 0.26/100000 at age 5–9 to a peak of
58.3/100000 at age 80–84. Following this, there is a down-
ward trend in incidence rate. The lifetime risk of ovarian
cancer in the general population is 1.7 percent. Most women
who are diagnosed with epithelial ovarian cancer (EOC) are
between the ages of 40 and 65.
3.DiagnosisandInitialTreatment
Unfortunately, the initial signs and symptoms of ovarian
cancer are vague. These can include nonspeciﬁc complaints
of bloating, gastrointestinal symptoms, and pain [3]. The
subtle nature of symptoms can often delay patient presen-
tation. It is important for a provider to retain a high index
of suspicion if a patient presents with abdominal or pelvic
symptoms, particularly if these symptoms occur daily, are
more severe than expected, or present as a constellation
of complaints. Secondary to lack of screening tools and
the indolent nature of presenting symptoms, ovarian cancer
often presents when patients have already progressed to
disseminated disease. A prior analysis by the International
Federation of Gynecology and Obstetrics showed that distri-
bution by stage is I (23 to 33 percent), II (9 to 13 percent), III2 Journal of Oncology
( 4 6t o4 7p e r c e n t ) ,a n dI V( 1 2t o1 6p e r c e n t )[ 4]. Those who
present with advanced stage are often incurable.
Cytoreduction is the goal in initial surgical therapy
for patients with ovarian cancer. Decreasing the remaining
tumor burden has been shown to improve response to post-
operative systemic chemotherapy. This ﬁnding is biologically
plausible, in that small tumors are better perfused and more
mitotically active, thereby allowing chemotherapeutic drugs
tohavebettereﬃcacy.Ameta-analysisofover53studieswith
advanced stage ovarian carcinoma treated with platinum-
based chemotherapy found a 5.5 percent increase in median
survival for every 10 percent increase in the proportion
of patients achieving maximal cytoreduction, which was
deﬁned as less than or equal to 3cm in the analysis [5].
The current standard of care for initial adjuvant
chemotherapy in EOC is a platinum drug, usually carbo-
platin, and a taxane. The Gynecologic Oncology Group
(GOG) evaluated the eﬃcacy of cisplatin versus carboplatin
in a noninferiority trial. The authors concluded that a
chemotherapeutic regimen consisting of carboplatin plus
paclitaxel results in less toxicity, is easier to administer, and
is not inferior, when compared with cisplatin plus paclitaxel
[6].
4.Second Lineand Targeted Therapy
Unfortunately, despite optimal cytoreduction and adequate
adjuvant therapy, many patients with EOC will experience
disease recurrence. Over 70–80 percent of patients will
relapse and ultimately die of their disease [7]. Therapy
for recurrent disease is varied and depends upon time to
recurrence.
Patients are categorized into groups based on their
disease-free period, including platinum-sensitive (those
patients who recur greater than 12 months after therapy),
partially platinum-sensitive (those who recur between 6–12
months after therapy), platinum-resistant (those who recur
before 6 months after therapy), and platinum-refractory
(those who never achieve disease free status). Tradition-
ally, patients who recur more than 6 months after initial
therapy are given a second course of platinum-taxane-
basedchemotherapy.Platinum-sensitivediseasehasagreater
than 50 percent response rate to single agent carboplatin,
while resistant disease has a 10–20 percent response rate
and refractory disease response is even lower [8]. The
latter groups are therefore typically treated with other FDA
approved chemotherapy regimens including pegylated lipo-
somal doxorubicin, gemcitabine, topotecan, and etoposide
[9].
The bane of ovarian cancer therapy is the failure
of currently established treatment protocols to allow for
cure of the disease at diagnosis, even in patients with
initially chemosensitive tumors. Despite eﬀorts of clinical
trials to identify more eﬃcacious regimens to overcome
the chemoresistance encountered after front-line platinum-
taxane treatment, clinical response to second-line therapy
continues to be short lived and results in only marginal
improvements in progression free and overall survival [8]. In
response to this challenge, the idea of overcoming resistant
disease with targeted therapy has come to the forefront of
investigation in ovarian cancer therapy.
5.Angiogenesis Targeted Therapy
Angiogenesis is the development of new blood vessels in
areas of new tissue growth. This is a normal phenomenon
associated with routine processes including wound healing
and embryogenesis. It is also an important process that
occurs almost universally in solid tumors as a response to the
expansionofthecancermassanditssubsequentgrowthaway
from existing blood supply. This causes the oxygen tension
to decrease beneath physiologic levels needed for oxidative
metabolism [10].
An important interplay of proangiogenic signaling
occurs in response to the hypoxic state. A protein called
hypoxia-inducible factor (HIF) 1 alpha is stabilized in these
conditions and enters the nucleus where it forms a complex
with another protein (HIF 1 beta) [11]. This complex is then
able to act as a transcription factor allowing upregulation of
growth factors including vascular endothelial growth factor
(VEGF) [12, 13]. The VEGF family includes six closely
related molecules, but the most important angiogenic agent
is VEGF-A.
Molecular markers of angiogenesis have been studied
in ovarian cancer. Prior studies have shown associations
between VEGF-A levels and microvessel density in primary
tumors and disease extent as well as progression-free and
overall survival following initial antiangiogenic therapy [14].
Preclinical models have also shown the importance of the
VEGF pathway in ascites formation [15, 16].
Bevacizumab is a monoclonal antibody directed against
VEGF-A. Studies evaluating this agent have shown improved
survival in colorectal [17], breast [18], and lung cancers
[19]. A GOG phase II study of bevacizumab in persistent
or recurrent EOC or primary peritoneal carcinoma was
performed by Burger et al. [20]. This study revealed a
21% clinical response rate. Of the 62 patients on trial,
25 experienced at least 6-months progression free survival
(PFS), with a median PFS of 4.7 months and median overall
survival of 17 months. This study was unique in that none
of the patients experienced gastrointestinal perforation, a
known complication of bevacizumab in other clinical trials.
Cannistra et al. performed a phase II trial of single agent
bevacizumab in patients with platinum-resistant disease
[21].AsopposedtotheGOGtrial,thisstudywasclosedearly
secondary to the proportion of patients that experienced GI
perforations (5/44), but the study did show a 16% response
rate and a median durable response of 12 weeks. Toxic
events that were similar between these two trials include
hypertensionandvascularthrombosis.Garciaandcolleagues
performed a phase II trial of bevacizumab that evaluated
the use of bevacizumab and low-dose metronomic oral
cyclophosphamide in recurrent ovarian cancer [22]. The
authorsfounda28%responseratewith6monthPFSof28%;
see Table 1.
Based on the activity of bevacizumab as documented in
these phase II trials, there are currently two trials that are
ongoingtoevaluatetheactivityofbevacizumabinthesettingJournal of Oncology 3
Table 1: Results of three pivotal trials evaluating bevacizumab in ovarian cancer. Burger et al. and Cannistra et al. evaluated bevacizumab as
a single agent whereas Garcia et al. evaluated bevacizumab with low-dose metronomic oral cyclophosphamide. All studies were performed
in patients with recurrent disease.
Author Progression free survival Overall survival Bowel perforation
Burger et al. 3.4 months 7.29 months 0%
Cannistra et al. 4.4 months 10.7 months 11.4%
Garcia et al. 7.2 months 16.9 months 5.7%
Table 2: Review of studies of antiangiogenic agents in recurrent or persistent ovarian cancer. RR: response rate, HTN: hypertension, RF:
renal failure, P/S: platinum-sensitive, P/R: platinum resistant. ∗2 conﬁrmed and one unconﬁrmed partial response. ∗∗1 unconﬁrmed partial
response.
Agent Authors RR Toxicities
VEGF trap Tew et al. 5/45 partial HTN, proteinuria, encephalopathy, RF
Cediranib Hirte et al. P/S: 3/17 partial∗
Diarrhea, HTN, fatigue, anorexia
P/R: 1/24 partial∗∗
of front line adjuvant therapy. The ﬁrst is GOG 218, a study
that evaluates stages III and IV EOC patients who have
undergone surgery and are subsequently randomized to one
of three arms; arm 1 utilizes the traditional chemotherapy
regimen of carboplatin (AUC 6) and paclitaxel (175mg/m2)
and placebo, arm 2 includes the active drugs of arm 1 and
adds bevacizumab (15mg/kg every 21 days for 6 cycles,
starting with cycle 2), while arm 3 includes the drugs of arm
2 and adds maintenance bevacizumab given every 21 days to
complete 22 cycles. A second trial is run by the Gynecologic
Cancer InterGroup in Europe (ICON7) and is an open label
trial. The ICON7 study population includes both high risk
early stage disease (stage I-IIa with grade 3 or clear cell
histology) and advanced disease IIb-IV EOC or primary
peritoneal cancer. Patients are randomized to one of two
arms: carboplatin and paclitaxel or carboplatin, paclitaxel,
and bevacizumab. The bevacizumab arm also includes a
maintenance schedule continuing the drug every three weeks
for 12 cycles. The study aims to evaluate PFS as a primary
endpoint and overall survival, duration of response, and
response rate as secondary endpoints [23].
Bevacizumab has also been studied in conjunction with
other targeted agents. A phase I study of bevacizumab
and a vascular disrupting agent (VDA) combretastatin 4A
phosphate (CA4P) in patients with advanced solid tumors
demonstrated no additive toxicity and the evidence for
eﬃcacy was encouraging [24]. This is of interest because
preclinical evidence exists for synergy between VDA, which
causes a surge in VEGF-stimulated circulating endothelial
progenitor cells, and bevacizumab, which suppresses this
induced eﬀect [25].
VEGF Trap is a fusion protein consisting of the extra-
cellular domains of human VEGF-1 and -2. This protein
binds to VEGF-A and placental growth factor. In mouse
models VEGF Trap treatment resulted in decreased ovarian
cancer growth and ascites [26]. Tew and colleagues reported
on a phase II study evaluating patients with recurrent,
platinum-resistant EOC. The participants received VEGF
trap (2 or 4mg/kg) administered intravenously every two
weeks. This study yielded an 11% partial response, with
grade 3/4 toxicities including hypertension, proteinuria,
encephalopathy, and renal failure [27]. A phase II trial
involving VEGF trap combined with docetaxel in patients
with recurrent EOC, primary peritoneal cancer or fallopian
tube cancer with measurable disease is currently ongoing
[28]. Patients in this study will receive VEGF trap at the
maximum tolerated dose (as determined in Phase I of the
trial which has closed to accrual) over 1 hour on day 1
of course 1, followed by VEGF trap IV over 1 hour and
docetaxel over 1 hour on day 1 in all subsequent courses. The
coursesrepeatevery21daysinabsenceofdiseaseprogression
or unacceptable toxicity.
C-kit is a growth factor receptor of the tyrosine kinase
subclass III family, the ligand of which is Stem Cell Factor,
and is normally expressed in many cell lines, including
gametocytes[29].C-kitsignalingpromotescellproliferation,
diﬀerentiation, migration, adhesion, and survival [30]. The
platelet derived growth factor receptor beta (PDGRF-B)
gene encodes a cell surface tyrosine kinase receptor for
members of the platelet derived growth factor family. This
receptor is essential for cell migration and development of
microvasculature.
Cediranib is an oral VEGFR-1, -2, and -3, PDGFR-
B, and c-kit inhibitor. Hirte et al. performed a phase II
trial of cediranib in patients with recurrent or persistent
EOC, primary peritoneal or fallopian tube cancers [31]. The
trial design initially included daily oral dosing of 45mg,
which was decreased to 30mg continuously secondary to
toxicity. Of the patients with platinum sensitive disease, 41%
responded to therapy, while those with platinum-resistant
disease demonstrated a 29% response rate. Signiﬁcant
side eﬀects included diarrhea, hypertension, fatigue, and
anorexia. Median time to progression was 4.1 months, while
medianoverallsurvivalwas11.9months.AphaseIIIstudyof
cediranib in patients with platinum sensitive recurrent EOC
is currently ongoing in Europe; see Table 2.4 Journal of Oncology
6. Epidermal Growth Factor Receptor
Epidermal growth factor receptor (EGFR) is overexpressed
in 70% of cancers and is associated with chemoresis-
tance, poor prognosis, and advanced disease at presentation
[32, 33]. The mechanism of growth factor receptors is
via activation of the intracellular tyrosine kinase domain,
which triggers downstream targets and subsequently cell
proliferation and survival [34]. Preclinical studies suggested
that inhibiting this target might reverse chemoresistance
and demonstrate antitumor activity [35–37]. Unfortunately,
clinical trials evaluating drugs aﬀecting these pathways, such
as studies of EGFR tyrosine kinase inhibitors (geﬁtinib and
erlotinib) and monoclonal antibodies directed against EGFR
(cetuximab, panitumumab, and matuzumab), have not been
met with signiﬁcant success, showing only modest eﬃcacy
[8].
Geﬁtinib is a small molecule tyrosine kinase inhibitor
that binds to the ATP-binding site of the EGF receptor
and thereby prevents its activation. A GOG phase II study
of geﬁtinib in patients with relapsed or persistent ovar-
ian or primary peritoneal carcinoma assessed the activity
and tolerability of a daily oral dose of 500mg. The trial
showed that only four of 27 eligible and evaluable patients
exhibited progression-free survival greater than 6 months.
One objective response was seen, and interestingly this
patient was found to have the rare presence of an EGFR
mutation. EGFR expression was associated with longer PFS
(P = .008) and possibly longer survival (P = .082).
Geﬁtinib was well tolerated, with dermatologic (15%) and
diarrhea (30%) the most common grade 3 toxicities [38]. A
phase II trial performed by the AGO Ovarian Cancer Study
group evaluated geﬁtinib (500mg/day) in combination with
tamoxifen (40mg/day) given until progression or unac-
ceptable toxicity in patients with platinum-resistant EOC
[39]. While this study demonstrated no tumor responses,
16 of 56 patients had stable disease. Notably, there was an
11% discontinuation rate secondary to side eﬀects including
diarrhea and skin rash.
Erlotinib is an oral epidermal growth factor receptor
(HER1/EGFR) tyrosine kinase inhibitor. Gordon and col-
leagues performed a phase II study in patients with refrac-
tory, recurrent, HER1/EGFR positive EOC [34]. Patients
received150mgerlotiniborallyonceadayforupto48weeks
or until disease progression or dose-limiting toxicity. This
study found little clinical activity, with an objective response
rate of 6% (2/34), both of which were partial responses.
Stable disease was seen in 15/34 patients. Rash (68%) and
diarrhea (38%) were the most frequent adverse events.
Erlotinib was recently investigated as a single agent medica-
tion in maintenance therapy after ﬁrst-line chemotherapy in
a large study performed by the European Organization for
Research and Treatment of Cancer (EORTC), with results
forthcoming.
Disappointment was also encountered in clinical trials
examiningerlotinibincombinationwithotheragents,where
toxicity led to premature termination [40]. A phase II
trial by Nimeiri and colleagues of bevacizumab (15mg/kg)
administered intravenously every 21 days and erlotinib
(150mg) given orally every day was performed in 13 patients
with recurrent ovarian, primary peritoneal and fallopian
tube cancer. This study showed a 15% response rate and
seven patients had a best response of stable disease. Two
patients had fatal gastrointestinal perforations, which lead to
the early termination of the trial.
Overexpression of ERBB2 is also found in patients with
ovarian cancer. Trastuzumab, or Herceptin, is a monoclonal
antibody directed against ERBB2, and has been studied in
a phase II trial by the GOG. This study evaluated the drug
in patients with recurrent or refractory ovarian or primary
peritoneal carcinoma with overexpression of HER2 [41].
Patients initially received trastuzumab at a dose of 4mg/kg,
then weekly at 2mg/kg. Patients without progressive or
excessive toxicity could continue indeﬁnitely, and those
with stable or responding disease at 8 weeks were oﬀered
treatment at a higher dose (4mg/kg) at time of progression.
The authors reported that only 7% of the patients responded
to treatment and a median time to progression of 2 months
was seen.
Pertuzumab is a monoclonal antibody that inhibits
dimerization of ERBB2 with EGFR, ERBB3, and ERBB4. A
phase II trial of single agent pertuzumab administered as
an intravenous loading dose of 840mg followed by 420mg
every three weeks (in cohort 1) and as 1050mg every three
weeks (in cohort 2) was performed in advanced, refractory
ovarian cancer. The authors reported a 4.3% partial response
rate and 6.8% of patients with stable disease lasting at least
6 months. Median PFS was 6.6 weeks [42]. Patients who
were phosphoHER2 positive had a trend toward higher
median PFS (20.9 weeks) versus those who were negative
(5.8 weeks, P = .14). Two trials have evaluated the eﬃcacy
of pertuzumab when combined with chemotherapy, one
phase II study in combination with carboplatin and another
phase II trial in combination with gemcitabine [43, 44]. The
gemcitabine and pertuzumab trial was performed in patients
with platinum resistant EOC, and there was the suggestion
of some beneﬁt of pertuzumab in patients with low levels of
ERBB3mRNAexpressionandplatinum-resistantdisease;see
Table 3.
7.MultikinaseInhibitors
Sorafenib is an oral multikinase inhibitor that targets
the mitogen-activated protein kinase (MAPK) pathway or
Raf/MEK/ERKpathway[45].ThisdrugalsoinhibitsVEGFR-
1, -2, and -3 and platelet-derived growth factor receptor
(PDGFR) beta tyrosine kinase activity. Sorafenib is currently
FDA-approved for treatment of advanced renal cell cancer,
and the biologic rationale for attempting its use in other
solid tumors is the fact that MAPK pathway is well conserved
evolutionarily and may serve as a central and common target
[23].
A phase II trial of single agent sorafenib in persistent or
recurrent EOC or primary peritoneal cancer was performed
by the GOG [46]. Patients received sorafenib 400mg orally
twice daily until disease progression or prohibitive toxicity.
Of the 59 patients with measurable disease, there were
2 partial responders and 20 patients with stable disease,Journal of Oncology 5
Table 3: Review of drugs in the epidermal growth factor receptor family that have been evaluated in ovarian cancer. RR: response rate, SD:
stable disease, HTN: hypertension.
Agent(s) Authors RR SD Toxicities
Geﬁtinib Schilder et al. 1/27 Dermatologic, diarrhea
Geﬁtinib + tamoxifen Wagner et al. 0/56 16/56 Diarrhea, skin rash
Erlotinib Gordon et al. 2/34 partial 15/34 Rash, diarrhea
Erlotinib + bevacizumab Nimeiri et al. 1/13 complete 7/13 Anemia, nausea, vomiting, HTN,
diarrhea, 2 fatal GI perforations 1/13 partial
Transtuzumab Bookman et al. 1/41 complete
2/41 partial
Pertuzumab Gordon et al. 5/107 partial 8/107 Diarrhea
30 patients had progressive disease reported, and 7 were
unable to have their tumor assessed. Grade 3 and 4 toxicities
included rash, gastrointestinal, cardiovascular, metabolic,
and pulmonary.
Sorafenibhasalsobeenstudiedinconjunctionwithother
medications. A Phase I dose escalation study of sorafenib
(200mg orally twice daily) and bevacizumab (5mg/kg
or 10mg/kg intravenously every two weeks) showed six
Response Evaluation Criteria in Solid Tumors (RECIST)
partialresponsesin13ovariancancerpatients,withduration
of response from 4 to over 22 months [47]. Unfortunately,
this combination yielded signiﬁcant toxicity, with grade 3
hypertension, diarrhea, hand-foot syndrome, thrombocy-
topenia, proteinuria, and two episodes of ﬁstula formation
at sites of disease response. A phase II trial evaluated
sorafenib in combination with gemcitabine [48]. Patients
were given gemcitabine 1000mg/m2 intravenously weekly
for 7 out of 8 weeks of the ﬁrst cycle, then weekly for
the ﬁrst 3 weeks of a 4-week cycle and sorafenib 400mg
orally twice daily continuously. Using RECIST criteria, the
authors reported 1 out of 18 evaluable patients had a partial
response and 5 had a conﬁrmed partial response by CA125
criteria. An additional 10 patients exhibited stable disease.
Median time to progression was 5.4 months and overall
survival was 13.3 months. The most frequent grade 3 and 4
toxicities were hematologic (lymphopenia, neutropenia, and
thrombocytopenia), fatigue,
hypokalemia, and hand-foot syndrome.
Imatinib mesylate inhibits abl, c-kit, and PDGFR tyro-
sine kinases, thereby inhibiting tumor growth. It is FDA
approved for some forms of adult and child chronic
m y e l o g e n o u sl e u k e m i aa sw e l la sg a s t r o i n t e s t i n a ls t r o m a l
tumors (GISTs). Activating mutations of kit have not been
found in ovarian cancers, but abnormal kit expression has
been described [49]. The activity of single agent imatinib in
patients with recurrent EOC has been poor. A phase II trial
of imatinib administered orally at 600mg daily for six weeks
and repeated in absence of measurable progressions was
performed in patients with platinum and taxane-resistant
ovarian and primary peritoneal cancer. This trial showed no
complete or partial responders during a median followup
of 6.6 months [50]. A phase II trial of imatinib mesylate
(400mg orally) in recurrent ovarian cancer with positive c-
kit or PDGFR found no objective responders and a median
PFS of only 2 months [51]. The GOG also conducted a
phase II trial of single agent imatinib (400mg orally twice
daily) in recurrent or persistent EOC or primary peritoneal
cancer [49]. Eligibility for this trial included expression of
at least one target (c-kit, PDGFR-alpha, PDGFR-beta) in
the tumor. Only 9/56 patients were progression free for at
least 6 months, with a median PFS of 2 months and median
overall survival of 16 months. The most common grade 3
and 4 toxicities included GI, pain, electrolyte disturbances,
dermatologic, and neutropenia; see Table 4 .
8. PARP Inhibition
Poly(ADP-ribose) polymerase (PARP) is an enzyme involved
in repair of DNA single-strand breaks using the base excision
repair pathway [52, 53]. A recent review by Yap et al. detailed
the mechanism by which PARP inhibition can lead to cancer
cell death. Inhibition of PARP leads to the accumulation
of DNA single-strand breaks, which may subsequently lead
to DNA double-strand breaks at replication forks [54]. In
normal cells, double-strand breaks would be repaired in
part by error-free homologous recombination DNA repair
mechanisms [8]. Two proteins involved in this process
are functional BRCA1 and BRCA2, which have a role
in homologous recombination repair and maintenance of
genomic stability [55]. If somatic mutations or epigenetic
silencing leads to the absence of either BRCA1 or BRCA2,
alternative DNA repair pathways such as nonhomologous
end joining are employed; this subsequently results in
chromosomalinstabilityandcelldeath[54].TheuseofPARP
inhibitors in BRCA mutation carriers exploits the concept
of synthetic lethality via combination of base excision repair
inhibition with a defective homologous DNA repair pathway
which results in the generation of unrepaired DNA single-
strand breaks, an accumulation of double-strand breaks,
collapsed replication forks, and eventual cell death [56–58];
see Figure 1 .
Olaparib is an oral small-molecular PARP inhibitor.
Preclinical studies conﬁrmed that BRCA-deﬁcient cells were
up to 1000-fold more sensitive than wild-type cells to PARP
inhibition [57]. Cells that are heterozygous for BRCA muta-
tions, with an intact homologous recombination function,
had a lack of sensitivity to PARP inhibitors similar to wild-
type cells. This ﬁnding suggests that a therapeutic index6 Journal of Oncology
Table 4:Reviewofmultikinaseinhibitorsthathavebeenstudiedinovariancancer.RR:responserate,SD:stabledisease,HTN:hypertension,
HFS: hand-foot syndrome.
Agent(s) Authors RR SD Toxicities
Sorafenib Matei et al. 2/59 partial 20/59 Rash, GI, cardiovascular, metabolic,
pulmonary
Sorafenib + bevacizumab Azad et al. 6/13 partial HTN, diarrhea, HFS, thrombocytopenia,
proteinuria, ﬁstula
Sorafenib + gemcitabine Welch et al. 6/18 partial 10/18 Lymphopenia, thrombocytopenia, HTN,
HFS, pain, neutropenia, hypokalemia
Imatinib Coleman et al. 0/12 4/12 Fatigue, nausea/vomiting, rash,
neutropenia
Imatinib Alberts et al. 0/19 Hematologic, metabolic
Imatinib Schilder et al. 1/56 complete Neutropenia, GI, dermatologic, pain,
electrolyte disturbances
PARP
inhibitor
DNA damage
DNA repair
Accumulation of single strand DNA breaks
Double strand breaks
Cell death
Repair of DNA
BRCA1/2
mutation
Figure 1: Poly(ADP-ribose) polymerase is involved in base excision repair of DNA single-strand breaks. If PARP is inhibited, these breaks
can accumulate, potentially leading to double-strand breaks. These double-strand breaks are normally repaired by error-free homologous
recombination, of which BRCA1 and BRCA2 proteins are involved. If these proteins are aﬀected by somatic mutation or epigenetic silencing,
eventual chromosomal instability and cell death can be seen.
for antitumor therapy may be present in BRCA-associated
ovarian cancer [54, 57].
In phase I trials, olaparib was well tolerated, and there
were no obvious diﬀerences in the pattern of toxicities
between BRCA and non-BRCA patients [59–61]. A phase I
trial in BRCA deﬁcient ovarian cancer included 41 BRCA1
mutation carriers, 8 BRCA2 mutation carriers, and one
patient with compelling family history for BRCA mutation.
Of the 46 patients evaluable for RECIST or Gynecologic
Cancer Intergroup CA125 response, 41% responded. An
additional 11% of patients had meaningful stabilization of
disease by RECIST criteria. Median response duration was
30 weeks. Responses were more frequent in the platinum-
sensitive group, but were also seen in platinum-refractory
and platinum-resistant populations. A phase I trial included
60 patients, 22 of which were carriers of a BRCA1 or
BRCA2 mutation and one had a strong family history of
BRCA-associated cancer but declined mutational testing
[62]. The olaparib dose and schedule were increased from
10mg daily for 2 of every 3 weeks to 600mg twice
daily continuously. Dose limiting toxicities including mood
alteration, fatigue, thrombocytopenia, and somnolence seen
at 400–600mg twice daily led to the recruitment of a
second cohort of patients consisting of only BRCA1 or 2
mutation carriers, who received olaparib at 200mg twice
daily. Objective antitumor activity was reported only in
mutation carriers.
A randomized phase II trial comparing olaparib (200
or 400mg orally twice daily) with pegylated liposomal dox-
orubicin (50mg/m2 monthly intravenous) in patients with
BRCA-mutated ovarian cancer with a platinum-free interval
of 0–12 months is currently underway (NCT00628251).
Another ongoing trial is a randomized placebo-controlled
study of olaparib (400mg orally twice daily) as maintenance
therapy in patients with serous/sporadic ovarian cancer at
high risk of early recurrence (NCT00753545).
9. Summary
Newer targeted therapies are undergoing evaluation in
ovarian cancer. The most promising at this time are those
directed towards inhibition of angiogenesis. Combining
targeted therapeutics has resulted in signiﬁcant toxicities,
tempering enthusiasm for this approach. The ﬁnding of
PARP inhibitors as potentially active agents in BRCA-
associated ovarian cancer further supports the importance
of screening patients for potential BRCA-associated disease
and oﬀering mutational testing when appropriate. Finally,
given that the patient population who has typically entered
trials evaluating targeted therapeutics includes those with
recurrent or resistant disease, perhaps the ﬁnding of stable
disease has some merit in the context of treatment eﬀective-
ness.Deeperunderstandingofbiologicalpathwaysinovarian
cancerwillbeneededtoselectpatientswhoenterthesetrials.Journal of Oncology 7
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